Novartis Nabs EU Approval of Mayzent for Secondary Progressive Multiple Sclerosis

The EMA approved Novartis’ Mayzent (siponimod) for treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

The marketing authorization was based on positive results from a clinical trial which compared the safety and efficacy of Mayzent versus placebo in a broad range of SPMS patients.

The European authorization makes Mayzent the first oral treatment for SPMS patients with active disease.